About Gamma-aminobutyric acid receptor subunit gamma-2
Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) is a protein
from Homo sapiens identified by UniProt accession
P18507, 475 residues long.
MolForge cross-references it against 0 known binders and
661 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit gamma-2 |
| UniProt accession | P18507 |
| Gene | GABRG2 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (661)
Diseases linked to this target (Open Targets).
- Generalized epilepsy with febrile seizures-plus · score 0.79
- Seizure · score 0.70
- epilepsy · score 0.70
- Lennox-Gastaut syndrome · score 0.64
- insomnia · score 0.61
- unipolar depression · score 0.60
- panic disorder · score 0.60
- Agitation · score 0.60
- pain · score 0.60
- anxiety disorder · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18507-F1 | alphafold | PREDICTED | 77.19 | — |
Amino-acid sequence (475 residues)
MSSPNIWSTG SSVYSTPVFS QKMTVWILLL LSLYPGFTSQ KSDDDYEDYA SNKTWVLTPK VPEGDVTVIL NNLLEGYDNK LRPDIGVKPT LIHTDMYVNS IGPVNAINME YTIDIFFAQT WYDRRLKFNS TIKVLRLNSN MVGKIWIPDT FFRNSKKADA HWITTPNRML RIWNDGRVLY TLRLTIDAEC QLQLHNFPMD EHSCPLEFSS YGYPREEIVY QWKRSSVEVG DTRSWRLYQF SFVGLRNTTE VVKTTSGDYV VMSVYFDLSR RMGYFTIQTY IPCTLIVVLS WVSFWINKDA VPARTSLGIT TVLTMTTLST IARKSLPKVS YVTAMDLFVS VCFIFVFSAL VEYGTLHYFV SNRKPSKDKD KKKKNPLLRM FSFKAPTIDI RPRSATIQMN NATHLQERDE EYGYECLDGK DCASFFCCFE DCRTGAWRHG RIHIRIAKMD SYARIFFPTA FCLFNLVYWV SYLYL
Explore Gamma-aminobutyric acid receptor subunit gamma-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets